GVR Report cover Prostate Cancer Therapeutics Market Report

Prostate Cancer Therapeutics Market Analysis By Drugs (Zytiga, Gonax, Lupron, Zoladex, Decapeptyl, Eligard, Vantas, Casodex, Xtandi, Taxotere, Jevtana, Provenge, Xofigo), By Region, And Segment Forecasts, 2018 - 2025

  • Report ID: GVR-1-68038-925-8
  • Number of Pages: 90
  • Format: Electronic (PDF)
  • Historical Range: 2014 - 2015
  • Industry: Healthcare

Industry Insights

The global prostate cancer therapeutics market size was valued at USD 7.9 billion in 2016 and is expected to grow at a CAGR of 4.8% over the forecast period. As per data published by the World Cancer Research Fund International, more than 1.1 million cases of prostate cancer were reported in 2012, which accounts for around 8 percent of the total tumor cases. Although the exact cause of prostate cancer is not known, factors associated with it include overweight, obesity, and history of any other tumorous growth. Even patients with cardiovascular diseases are prone to metastasis of cancer. Thus, the rising incidence rate of the above-mentioned conditions is driving the market growth.

U.S. prostate cancer therapeutics market, by drug class, 2014 - 2025 (USD Billion)

U.S. prostate cancer therapeutics market

The adoption of innovative technologies in screening & diagnostic tests is projected to drive growth. The incorporation of multiparametric MRI (mp-MRI) can significantly improve the detection of tumors and also provide confirmation whether there is a need for tissue biopsy. In addition, market players are investing in research for the development of therapeutic products for the treatment of such tumors. For instance, there is a strong pipeline of products such as Tc-99m (Progenics), radium-223 dichloride (Xofigo, Bayer), ODM-201 (Orion and Bayer), which are in their phase 3 studies and are projected to enter the market in the near future. In addition, many generic products are likely to enter the market owing to the expiry of patents of the major existing products during the forecast period. Thus, these factors are expected to drive growth.

Along with screening & diagnostic tests, awareness about the availability of medicines amongst public is also of prime importance to break the social stigma associated with tumor treatment and encourage patients to avail treatment in time. The governments of developed countries are taking efforts to conduct & implement programs for creating awareness of screening tests, such as Prostate-Specific Antigen (PSA) blood tests and Digital Rectal Exam (DRE) for male patients above 50 years. Prostate Cancer Canada has been established to support research, cure, and prevention of prostate cancer. Such awareness programs are also being undertaken in developing countries like China, India, & Brazil.

However, the high costs associated with a tissue biopsy, especially during the advanced stage of tumor and consultation fees of the physician is expected to slow down growth. In addition, factors such as poor reimbursement of treatment costs may affect the adoption rate of treatment procedures negatively.

Product Insights

Prostate cancer is one of the most common cancers diagnosed amongst men aging over 45 years. On-time screening and early diagnosis through PSA and DRE increase the success rate of the treatment regimen. The market is segmented into hormonal therapy that includes Luteinizing Hormone-Releasing Hormone (LHRH) agonist, LHRH antagonist, & anti-androgen; chemotherapy; immunotherapy; and targeted therapy.

Global prostate cancer market, by hormonal therapy 2016 (%)

Global prostate cancer market

Hormonal therapy, also called as Androgen Deprivation Therapy (ADT), aims to reduce levels of the male hormone, called androgens that stimulate the growth of cancer. Major players offering drugs under this segment are Johnson & Johnson; Astellas Pharma, Inc.; Astellas Pharma, Inc.; Medivation, Inc.; Sanofi; Valeant Pharmaceuticals North America LLC (Dendreon Corporation); and Bayer AG.

In 2011, Zytiga by Johnson & Johnson received FDA approval in 2011. This drug is a gold standard for the treatment of prostate cancer and is witnessing a rapid rise in sales year on year. Zytiga’s composition of matter patent expired in 2016. Astellas Pharma, Inc.’s brand Xtandi is a threat to Zytiga. Sales of Xtandi are already at par with Zytiga as patients are using it for long-term treatment and the product is gaining popularity amongst urologists. Thus, sales of Xtandi are increasing the revenue generated by the hormonal drug class. Thus, this segment holds the largest share.

However, rapid development & adoption of immunotherapy drugs are expected to result in the fast growth of this drug class. Provenge by Valeant Pharmaceuticals North America LLC (Dendreon Corporation) dominates this drug class. This drug is mainly used in the treatment of advanced or metastatic tumors. Furthermore, there are many promising drugs belonging to this drug class in the pipeline, such as INO-5150 SynCon immunotherapy targeting and PROSTVAC (Bavarian Nordic), which are expected to propel the demand for immunotherapies over the forecast period.

Regional Insights

North America was leading the global market with the largest revenue share in 2016. Rising prevalence and high mortality rate of prostate cancer in the U.S. are the primary reasons responsible for the dominance of North America in the market. Furthermore, this region is witnessing high investment in R&D for the development of newer immunotherapies and targeted drug therapies to treat such tumors.

Asia Pacific is anticipated to be the fastest-growing market over the forecast period. Rising awareness of such tumors would primarily drive growth. Governments of various countries in this region are playing a vital role in creating awareness through programs and online portals that provide detailed information regarding screening & diagnosis through PSA blood tests and DRE for male patients over 50 years of age.

Adoption of new technologies, improving healthcare infrastructure, and growing investments by market players for the development of immunotherapies and targeted therapies, which is resulting in a strong pipeline, are some of the factors expected to trigger growth in the Asia Pacific region. In China, major players are collaborating with local & government institutions such as the Chinese Urological Association to conduct research activities for the treatment of prostate cancer. As a result, Asia Pacific is projected to be the fastest-growing region.

Competitive Insights

Some of the major players include, but are not limited to, Johnson & Johnson; Astella, Inc.; Sanofi; Ipsen; Bayer AG; AstraZeneca; and Valeant Pharmaceuticals North America LLC (Dendreon Corporation). These major players dominate the market due to their strong brand identity coupled with a wide geographic reach.

Report Scope



Base year for estimation


Actual estimates/Historical data

2014 - 2015

Forecast period

2017 - 2025

Market representation                                                  

Revenue in USD Billion and CAGR from 2017 to 2025

Regional scope

North America, Europe, Asia Pacific, Latin America, and Middle East & Africa

Country scope

The U.S., Canada, Germany, The U.K., China, India, Brazil, Mexico, and South Africa

Report coverage              

Revenue forecast, company share, competitive landscape, growth factors and trends

15% free customization scope (equivalent to 5 analyst working days)

If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization

Segments Covered in the Report

This report forecasts revenue growth at global, regional & country levels and provides an analysis of the latest trends and opportunities in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the Prostate Cancer Therapeutics Market on the basis of drugs and region:

  • Drugs Outlook (Revenue, USD Billion; 2014 - 2025)

    • Hormonal Therapy

      • Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists

        • Zytiga

        • Gonax

      • Luteinizing Hormone-Releasing Hormone (LHRH) Agonists

        • Lupron

        • Zoladex

        • Eligard

        • Decapeptyl

        • Vantas

        • Others

      • Anti-Androgen

        • Xtandi

        • Casodex

    • Chemotherapy

      • Taxotere

      • Jevtana

    • Immunotherapy

      • Provenge

    • Targeted Therapy

      • Xofigo

  • Regional Outlook (Revenue, USD Billion; 2014 - 2025)

    • North America

      • The U.S.

      • Canada

    • Europe

      • Germany

      • The U.K.

    • Asia Pacific

      • China

      • Japan

    • Latin America

      • Mexico

      • Brazil

    • MEA

      • South Africa




This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.



We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon gvr sidebar D&B icon gvr sidebar

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.